Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors

Ryan R Woods; Glenn J Lesser

doi:10.1007/s11864-023-01116-w

Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors

Curr Treat Options Oncol. 2023 Sep;24(9):1293-1303. doi: 10.1007/s11864-023-01116-w. Epub 2023 Jul 6.

Authors

Ryan R Woods¹, Glenn J Lesser²

Affiliations

¹ Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA. rwoods@wakehealth.edu.
² Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA.

Abstract

Patients with primary brain tumors are at a substantially elevated risk of venous thromboembolism (VTE) compared to other disease states or other forms of malignancy. Deep venous thrombosis (DVT) and pulmonary embolism (PE), often complicate the care of patients with primary brain tumors, and treatment may pose specific unique risks and considerations for management. This paper critically reviews the relevant literature and the most common treatment options in addition to a discussion regarding the relative risk considerations for neurooncology patients facing thromboembolic disease.

Keywords: Anticoagulation; Brain tumor anticoagulation; Deep venous thrombosis; Glioblastoma multiforme; Pulmonary embolism; Thrombosis; VTE; Venous Thromboembolism.

Publication types

Review

MeSH terms

Anticoagulants / therapeutic use
Brain Neoplasms* / complications
Brain Neoplasms* / therapy
Humans
Pulmonary Embolism* / diagnosis
Pulmonary Embolism* / etiology
Pulmonary Embolism* / therapy
Risk Factors
Venous Thromboembolism* / diagnosis
Venous Thromboembolism* / etiology
Venous Thromboembolism* / therapy
Venous Thrombosis* / diagnosis
Venous Thrombosis* / etiology
Venous Thrombosis* / therapy

Substances

Anticoagulants